N‐acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta‐analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and Objectives: Recent neurobiological evidences along with clinical observations justify the use of N‐acetylcysteine (NAC) as a medication for craving. The objective of our study was to assess the evidence of efficacy of NAC for craving in substance use disorders in randomized clinical trials (RCTs). Methods: Systematic review of the RCTs literature (PROSPERO number 56698) until February, 2017, using MEDLINE, Cochrane Library and clinicaltrials.gov. We included seven RCTs (n = 245); most with small‐to‐moderate sample sizes. The main outcome was the Hedges’ g for continuous scores in a random‐effects model. Heterogeneity was evaluated with the I2 and the χ2 test. Publication bias was evaluated using the Begg's funnel plot and the Egger's test. Meta‐regression was performed using the random‐effects model. Results: Comparing NAC versus placebo, NAC was significantly superior for craving symptoms (Hedges’ g = 0.94; 95%CI 0.55–1.33). The funnel plot showed the risk of publication bias was low and between‐study heterogeneity was not significant (I2 = 44.4%, p = 0.07 for the χ2 test). A subgroup analysis performed using meta‐regression showed no particular influence. Discussion and Conclusions: NAC was superior to placebo for craving reduction in SUDs. The relatively small number of trials and their heterogeneous methodology were possible limitations; however, these positive thrilling results stimulate further studies for clarifying the potential impact of NAC for craving symptoms in SUDs.Scientific Significance: The safety profile of NAC and favorable tolerability, in addition to being an over‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs. Scientific Significance: The safety profile of NAC and its favorable tolerability, in addition to being anover‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs. (Am J Addict 2017;26:660–666)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission
Kalivas, P. W., Volkow, N., & Seamans, J. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.005 · Cited by 657
Neurobiologic processes in drug reward and addiction
Adinoff, B. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490910844 · Cited by 546
Sinha, R., Garcia, M., Paliwal, P., Kreek, M. J., & Rounsaville, B. J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.324 · Cited by 528
Grant, J. E., Odlaug, B. L., & Won Kim, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.60 · Cited by 424
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Zhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225
Repeated N-Acetylcysteine Administration Alters Plasticity-Dependent Effects of Cocaine
Madayag, A., Lobner, D., Kau, K. S., Mantsch, J. R., Abdulhameed, O., Hearing, M., Grier, M. D., & Baker, D. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-07.2007 · Cited by 225
Liechti, M. E., Lhuillier, L., Kaupmann, K., & Markou, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-07.2007 · Cited by 193
Glutathione: a novel treatment target in psychiatry
Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.001 · Cited by 183
Self-citation
Cited by
Responding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Raghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
Self-citationNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Orally-administered NAC appears to be well tolerated, with the most common adverse effects being nausea and diarrhea [212, 222].”
BackgroundPharmacological Treatment of Youth Substance Use Disorders
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L., & Gray, K. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0009 · Cited by 79
Tyagi (2019) · doi:10.1016/j.biopsych.2018.11.019 · Cited by 1
Metadata
- Authors
- Duailibi, M. S., Cordeiro, Q., Brietzke, E., Ribeiro, M., LaRowe, S., Berk, M., & Trevizol, A. P.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2017-09-12
- Volume
- 26
- Issue
- 7
- Pages
- 660-666
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- OpenAlex
- W2756375477
- Cited by
- 82
- References
- 13
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N‐acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/ajad.12620
- The paper
- Duailibi, M. S., Cordeiro, Q., Brietzke, E., Ribeiro, M., LaRowe, S., Berk, M., & Trevizol, A. P. (2017). N‐acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta‐analysis. The American Journal on Addictions. https://doi.org/10.1111/ajad.12620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.